REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 Nov 2024 15:02:32 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

05 Nov 2024 08:00:30 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 Oct 2024 15:05:23 By Nasdaq GlobeNewswire

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 Oct 2024 03:15:00 By Nasdaq GlobeNewswire

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 Oct 2024 05:00:49 By Nasdaq GlobeNewswire

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 Oct 2024 15:05:39 By Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 Aug 2024 15:05:41 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 Jul 2024 15:05:11 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 Jul 2024 11:00:53 By Nasdaq GlobeNewswire

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 15:05:28 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

08 May 2024 15:02:54 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

01 May 2024 15:05:56 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 Apr 2024 14:34:07 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 Apr 2024 10:36:55 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

04 Apr 2024 15:05:04 By Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 Mar 2024 15:05:40 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 Feb 2024 15:05:50 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 Feb 2024 15:05:47 By Nasdaq GlobeNewswire